Johnson & Johnson vaccine paused over rare blood clots
The US, South Africa and European Union will temporarily stop the rollout of the Johnson & Johnson Covid vaccine, following reports of rare blood clotting
Johnson & Johnson vaccine paused over rare blood clots photo credit: bbc.co.uk
The US, South Africa and European Union will temporarily stop the rollout of the Johnson & Johnson Covid vaccine, following reports of rare blood clotting.
Johnson & Johnson
According to the US Food and Drug administration (FDA), six cases were detected in more than 6.8 million doses of the vaccine. It follows similar cases after doses of the AstraZeneca vaccine, which prompted curbs to its use.
Johnson & Johnson has paused its EU rollout, which started this week.
The FDA recommended this temporary pause, “out of an abundance of caution.”
It was confirmed that one patient died from blood clotting complications and another is in critical condition. All six cases were in women aged between 18 and 48, with symptoms appearing six to thirteen days after vaccination.
ALSO READ: Blood clots: comparing the AstraZeneca vaccine and the contraceptive pill
